The UK NSC recommendation on Medium Chain Acyl CoA Dehydrogenase Deficiency (MCADD) screening in newborns (currently in consultation)
Find general information about population health screening.
More about MCADD
Fatty acids are one of the body's fuels: oxidation is the process by which they are broken down to release energy. This process has many steps, each catalysed by a different enzyme. Fatty acid oxidation (FAO) disorders result from deficiency of one of these enzymes.
MCADD is the commonest FAO disorder, affecting between 1 in 10,000 and 1 in 20,000 newborn babies.
Patients with MCADD deficiency are healthy most of the time. Infections or prolonged fasting, however, can lead to drowsiness and coma or sudden death. MCADD is treated through dietary management.
Further information about MCADD and its management can be found in the "Newborn screening for medium chain acyl CoA dehydrogenase deficiency" article, which can be downloaded from the 'related documents' section on this page.
Screening in the UK
Compare how screening is offered across the UK.
• British Dietetic Association
The stakeholder groups will be involved when the recommendation is next reviewed. If you think your organisation should be added, please contact us. More information for stakeholders can be found in appendix C of the UK NSC evidence review process.
Recommendation Review History
On 7 February 2007, the English Health Minister announced that all newborn babies in England are to be offered screening for MCADD by March 2009.
As of February 2009, all babies in England are offered screening for MCADD and a reception was held in March 2009 at the Houses of Parliament to launch this successful implementation. See the UCL Institute of Child Health press release.
The full report into prevalence, predictive value and test validity of screening for MCADD, based on 1.5 million babies, was published in 2011 and can be found here.
Related documentsMCADD Pilot Study Summary (PDF document, 119KB, 22/01/15)
Confidentiality and disclosure
Information provided in response to this consultation, including personal information, may be subject to publication or release to other parties or to disclosure in accordance with the access to information regimes (these are primarily the Freedom of Information Act 2000, the Data Protection Act 1998, and the Environmental Information Regulations 2004). If you want information, including personal data that you provide to be treated as confidential, please be aware that, under the FOIA, there is a statutory Code of Practice with which public authorities must comply and which deals, amongst other things, with obligations of confidence.
In view of this it would be helpful if you could explain to us why you regard the information you have provided as confidential. If we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. An automatic confidentiality disclaimer generated by your IT system will not, of itself, be regarded as binding on the UK National Screening Committee.
Any request for information to be treated in confidence will be taken into consideration in the publication of responses to the consultation. The UK National Screening Committee intends to publish all responses following the closure of the consultation period, however we will not publish responses from respondents who request that any of the information in their response, including personal data, should be handled in confidence. The UK National Screening Committee reserves the right not to publish or take into account any representations which are openly offensive or defamatory.
More optionsGo to top